Navigation Links
Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming Bank of America 37th Annual Investment Conference in San Francisco. Dr. Henderson's presentation will take place on Wednesday, September 19th at 8:30 am PT.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2019)... ... October 30, 2019 , ... ... the many roles innovation and technology play in educating the next generation of ... hands-on learning opportunities and presentations by WesternU administrators and representatives of companies working ...
(Date:10/26/2019)... ... October 24, 2019 , ... ... Bichsel Medical Marketing Group (BMMG), a boutique healthcare-specific marketing firm, to ... of its in-house Healthcare Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical ...
(Date:10/22/2019)... ... October 22, 2019 , ... ... announced that its lead program, DBI-001, met its primary safety endpoints, with no ... phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). ...
(Date:10/10/2019)... BETHESDA, Md. (PRWEB) , ... October 09, 2019 ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed ... place 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a ...
Breaking Biology Technology:
(Date:11/12/2019)... ... 12, 2019 , ... The Arnold and Mabel Beckman Foundation ... institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data Science ... for the acquisition of instrumentation, development and maintenance; support for data science collaborations ...
(Date:11/7/2019)... ... ... R3 Stem Cell is now offering its comprehensive Online Stem Cell ... use during checkout is FIFTYOFF and applies to both the one month access and ... with over 12,000 successful stem cell procedures performed nationwide. A couple years ago, R3 ...
(Date:11/5/2019)... ... November 05, 2019 , ... Dr. Lauren Kopp ... dentistry to Seattle, WA, including porcelain veneers , smile makeovers, dental implants, ... University of Washington, Dr. Kopp is passionate about serving her Seattle community with ...
Breaking Biology News(10 mins):